Analysis underscores Multaq's stroke-preventing effects

09/3/2008 | Reuters

An analysis of a clinical study for Sanofi-Aventis' Multaq found that the drug lowered stroke risk by 34% in patients with atrial fibrillation compared with those on placebo. The effect was sustained during the trial's follow-up period, which lasted from 12 to 30 months. The findings support previous research showing that Multaq combined with standard therapy decreased cardiovascular hospitalizations or death by 24%.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX